MKI67 and breast carcinoma: A recent assessment by the International Ki67 in Breast Cancer Working Group confirmed substantial inter-observer/laboratory variability in the range of >5 to <30% and thus recommends that Ki67 analysis avoids this range to drive patient care and estimate prognosis [28].